A monoclonal antibody-based immunoassay for measuring the potency of 2009 pandemic influenza H1N1 vaccines

Influenza and other Respiratory Viruses

Volumn 8, Issue 5, 2014, Pages 587-595

  Schmeisser, Falko ^a   Vasudevan, Anupama ^a   Soto, Jackeline ^a   Kumar, Arunima ^a   Williams, Ollie ^a   Weir, Jerry P ^a  

^a CENTER FOR BIOLOGICS EVALUATION AND RESEARCH   (United States)

Author keywords

Influenza virus vaccine; Monoclonal antibody; Potency assay

Indexed keywords

EPITOPE; INFLUENZA A/CALIFORNIA VIRUS HEMAGGLUTININ; INFLUENZA A/CALIFORNIA VIRUS HEMAGGLUTININ MONOCLONAL ANTIBODY; INFLUENZA VACCINE; INFLUENZA VIRUS HEMAGGLUTININ; MONOCLONAL ANTIBODY; POLYCLONAL ANTIBODY; TRIPLE VACCINE; UNCLASSIFIED DRUG; VIRUS ANTIBODY; H1N1 VIRUS HEMAGGLUTININ; INACTIVATED VACCINE;

2009 H1N1 INFLUENZA; ARTICLE; DRUG POTENCY; EC50; ENZYME LINKED IMMUNOSORBENT ASSAY; HEMAGGLUTINATION INHIBITION; IMMUNODIFFUSION; INFLUENZA VIRUS A H1N1; NONHUMAN; PASSIVE IMMUNIZATION; PRIORITY JOURNAL; VACCINE PRODUCTION; ANIMAL; CHEMISTRY; EVALUATION STUDY; HUMAN; INFLUENZA; MOUSE; PROCEDURES; VIROLOGY;

ANIMALS; ANTIBODIES, MONOCLONAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; HEMAGGLUTININ GLYCOPROTEINS, INFLUENZA VIRUS; HUMANS; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA VACCINES; INFLUENZA, HUMAN; MICE; VACCINES, INACTIVATED;

EID: 84908037934     PISSN: 17502640     EISSN: 17502659     Source Type: Journal    
DOI: 10.1111/irv.12272     Document Type: Article

References (28)

1. Wood JM, Schild GC, Newman RW, Seagroatt V. An improved single-radial-immunodiffusion technique for the assay of influenza haemagglutinin antigen: application for potency determinations of inactivated whole virus and subunit vaccines. J Biol Stand 1977; 5:237-247.
2. Williams MS. Single-radial-immunodiffusion as an in vitro potency assay for human inactivated viral vaccines. Vet Microbiol 1993; 37:253-262.
3. Minor PD, Engelhardt OG, Wood JM et al. Current challenges in implementing cell-derived influenza vaccines: implications for production and regulation, July 2007, NIBSC, Potters Bar, UK. Vaccine 2009; 27:2907-2913.
4. Cate TR, Couch RB, Parker D, Baxter B. Reactogenicity, immunogenicity, and antibody persistence in adults given inactivated influenza virus vaccines - 1978. Rev Infect Dis 1983; 5:737-747.
5. La Montagne JR, Noble GR, Quinnan GV et al. Summary of clinical trials of inactivated influenza vaccine - 1978. Rev Infect Dis 1983; 5:723-736.
6. Quinnan GV, Schooley R, Dolin R, Ennis FA, Gross P, Gwaltney JM. Serologic responses and systemic reactions in adults after vaccination with monovalent A/USSR/77 and trivalent A/USSR/77, A/Texas/77, B/Hong Kong/72 influenza vaccines. Rev Infect Dis 1983; 5:748-757.
7. Wright PF, Cherry JD, Foy HM et al. Antigenicity and reactogenicity of influenza A/USSR/77 virus vaccine in children-a multicentered evaluation of dosage and safety. Rev Infect Dis 1983; 5:758-764.
8. Hobson D, Curry RL, Beare AS, Ward-Gardner A. The role of serum haemagglutination-inhibiting antibody in protection against challenge infection with influenza A2 and B viruses. J Hyg (Lond) 1972; 70:767-777.
9. Hardy S, Eichelberger M, Griffiths E, Weir JP, Wood D, Alfonso C. Confronting the next pandemic-workshop on lessons learned from potency testing of pandemic (H1N1) 2009 influenza vaccines and considerations for future potency tests, Ottawa, Canada, July 27-29, 2010. Influenza Other Respir Viruses 2011; 5:438-442.
10. Kapteyn JC, Porre AM, de Rond EJ et al. HPLC-based quantification of haemagglutinin in the production of egg- and MDCK cell-derived influenza virus seasonal and pandemic vaccines. Vaccine 2009; 27:1468-1477.
11. Garcia-Canas V, Lorbetskie B, Bertrand D, Cyr TD, Girard M. Selective and quantitative detection of influenza virus proteins in commercial vaccines using two-dimensional high-performance liquid chromatography and fluorescence detection. Anal Chem 2007; 79:3164-3172.
12. Williams TL, Pirkle JL, Barr JR. Simultaneous quantification of hemagglutinin and neuraminidase of influenza virus using isotope dilution mass spectrometry. Vaccine 2012; 30:2475-2482.
13. Williams TL, Luna L, Guo Z et al. Quantification of influenza virus hemagglutinins in complex mixtures using isotope dilution tandem mass spectrometry. Vaccine 2008; 26:2510-2520.
14. Getie-Kebtie M, Chen D, Eichelberger M, Alterman M. Proteomics-based characterization of hemagglutinins in different strains of influenza virus. Proteomics Clin Appl 2009; 3:979-988.
15. Creskey MC, Li C, Wang J et al. Simultaneous quantification of the viral antigens hemagglutinin and neuraminidase in influenza vaccines by LC-MSE. Vaccine 2012; 30:4762-4770.
16. Nilsson CE, Abbas S, Bennemo M, Larsson A, Hamalainen MD, Frostell-Karlsson A. A novel assay for influenza virus quantification using surface plasmon resonance. Vaccine 2010; 28:759-766.
17. Bodle J, Verity EE, Ong C et al. Development of an enzyme-linked immunoassay for the quantitation of influenza haemagglutinin: an alternative method to single radial immunodiffusion. Influenza Other Respir Viruses 2013; 7:191-200.
18. Hashem AM, Gravel C, Farnsworth A et al. A novel synthetic receptor-based immunoassay for influenza vaccine quantification. PLoS ONE 2013; 8:e55428.
19. Robertson JS, Nicolson C, Harvey R et al. The development of vaccine viruses against pandemic A(H1N1) influenza. Vaccine 2011; 29:1836-1843.
20. Schmeisser F, Friedman R, Besho J et al. Neutralizing and protective epitopes of the 2009 pandemic influenza H1N1 hemagglutinin. Influenza Other Respir Viruses 2013; 7:480-490.
21. Schmeisser F, Adamo JE, Blumberg B et al. Production and characterization of mammalian virus-like particles from modified vaccinia virus Ankara vectors expressing influenza H5N1 hemagglutinin and neuraminidase. Vaccine 2012; 30:3413-3422.
22. Williams MS, Mayner RE, Daniel NJ et al. New developments in the measurement of the hemagglutinin content of influenza virus vaccines by single-radial-immunodiffusion. J Biol Stand 1980; 8:289-296.
23. Vodeiko GM, Weir JP. Determination of H5N1 vaccine potency using reference antisera from heterologous strains of influenza. Influenza Other Respir Viruses 2012; 6:176-187.
24. Schmeisser F, Vodeiko GM, Lugovtsev VY, Stout RR, Weir JP. An alternative method for preparation of pandemic influenza strain-specific antibody for vaccine potency determination. Vaccine 2010; 28:2442-2449.
25. Reno PW, Hoffmann EM. Enhancement of hemagglutination inhibition by complement. Infect Immun 1972; 6:945-951.
26. Feng JQ, Mozdzanowska K, Gerhard W. Complement component C1q enhances the biological activity of influenza virus hemagglutinin-specific antibodies depending on their fine antigen specificity and heavy-chain isotype. J Virol 2002; 76:1369-1378.
27. Gerdil C. The annual production cycle for influenza vaccine. Vaccine 2003; 21:1776-1779.
28. van de Donk HJ, de Jong JC, van Olderen MF, Osterhaus AD. Monoclonal antibodies for the control of influenza virus vaccines. Dev Biol Stand 1984; 57:251-255.